EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies

Guillermo Sánchez-Rodríguez, Lluís Puig iD

International Journal of Molecular Sciences · 18.06.2023 · 24 (12) · 10305

DOI: 10.3390/ijms241210305 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 18.06.2023. Verfasst von Guillermo Sánchez-Rodríguez und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Carrer de Sant Quintí, 89, 08041 Barcelona, Spain. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Psoriasis. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The interleukin 17 (IL-17) family, a subset of cytokines consisting of IL-17A-F, plays crucial roles in host defence against microbial organisms and the development of inflammatory diseases, including psoriasis (PsO), axial spondyloarthritis (axSpA), and psoriatic arthritis (PsA). IL-17A is the signature cytokine produced by T helper 17 (Th17) cells and is considered the most biologically active form. The pathogenetic involvement of IL-17A in these conditions has been confirmed, and its blockade with biological agents has provided a highly effective therapeutical approach. IL-17F is also overexpressed in the skin and synovial tissues of patients with these diseases, and recent studies suggest its involvement in promoting inflammation and tissue damage in axSpA and PsA. The simultaneous targeting of IL-17A and IL-17F by dual inhibitors and bispecific antibodies may improve the management of Pso, PsA, and axSpA, as demonstrated in the pivotal studies of dual specific antibodies such as bimekizumab. The present review focuses on the role of IL-17F and its therapeutic blockade in axSpA and PsA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, PsoriaticPsoriasisHumansInterleukin-17InflammationSkinCytokines

Stichwörter der Autor:innen

axial spondyloarthritisbimekizumabinterleukin 17Fpsoriasispsoriatic arthritissonelokimab

Substanzen

Interleukin-17Cytokines

Autor:innen und Institutionen

  • Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Carrer de Sant Quintí, 89, 08041 Barcelona, Spain.

ORCID-Profile: Lluís Puig

Zitieren

APA

Sánchez-Rodríguez, G., & Puig, L. (2023). Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies. International Journal of Molecular Sciences, 24(12), 10305. https://doi.org/10.3390/ijms241210305

Vancouver

Sánchez-Rodríguez G, Puig L. Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies. International Journal of Molecular Sciences. 2023;24(12):10305. doi:10.3390/ijms241210305

BibTeX
@article{SnchezRodrguez2023,
  author = {Sánchez-Rodríguez, Guillermo and Puig, Lluís},
  title = {Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {12},
  pages = {10305},
  doi = {10.3390/ijms241210305}
}
Kostenlos starten →